Palbociclib is used in combination with letrozole (postmenopausal women or men) or with fulvestrant (disease progression following hormonal therapy) in patients with hormone receptor (HR)-positive, HER-2 negative advanced or metastatic breast cancer. It belongs to the group of medicines called antineoplastics.
